Edesa Biotech
Markham
About Edesa Biotech
Edesa Biotech is a clinical-stage private company focused on developing treatments for dermatological and anorectal diseases. The initial focus is on developing novel, safe and potent alternatives to steroids for Allergic Contact Dermatitis, Hemorrhoids, and Anal Fissures. Edesa Biotech’s lead asset, EB01 is a novel non-steroidal anti-inflammatory molecule for the treatment of allergic contact dermatitis which has already demonstrated statistically significant improvements in multiple clinical studies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $80.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: nasdaq:EDSA
- Website: edesabiotech.com
- Phone: (905)-475 1234
Industries & Categories
Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/edesa-biotech-121529 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.